Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Gooch

Nurse Practitioner Alliance, OH Nurse Practitioner

NPI 1881007706 CMS profile 11133290

1207 W State St Ste N, Alliance, OH 44601

Open in the dashboard

General payments

$4,022

273 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Gooch of Alliance, OH is reported in the CMS Open Payments database as having received $4,022 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $753 44
2024 General $882 63
2023 General $532 44
2022 General $838 54
2021 General $1,016 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Gooch
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Matthew Gooch were reported at $753. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Matthew Gooch Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,016 $135 $40–$426 $132
2022 $838 $152 $48–$470 $149
2023 $532 $166 $54–$529 $160
2024 $882 $173 $55–$556 $164
2025 $753 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $707 59 payments
  2. AbbVie, Inc. $418 30 payments
  3. Novo Nordisk Inc $414 37 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $283 25 payments
  5. Lilly USA, LLC $258 17 payments
  6. AstraZeneca Pharmaceuticals LP $254 16 payments
  7. Welch Allyn $225 1 payment
  8. Amgen Inc. $203 7 payments
  9. GlaxoSmithKline, LLC. $188 13 payments
  10. Antares Pharma, Inc. $101 6 payments
  11. Other $971 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,785 271 payments
  2. Long term medical supply or device loan $225 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT $335 41 payments
  2. ZAVZPRET $332 28 payments
  3. Ozempic $279 31 payments
  4. VRAYLAR $269 20 payments
  5. RYBELSUS $262 30 payments
  6. ELIQUIS $243 21 payments
  7. CardioPerfect PRO ECG Recorder $225 1 payment
  8. BREZTRI $197 12 payments
  9. TRELEGY ELLIPTA $188 13 payments
  10. KRYSTEXXA $185 6 payments
  11. Other $2,861 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

10,526

Median for Nurse Practitioner: 389

Drug cost

$826,718

Median for Nurse Practitioner: $21,885

Branded share of claims

18.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 140 $152,033
Trulicity Dulaglutide Brand 78 $118,540
Eliquis Apixaban Brand 114 $100,013
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 107 $96,811
Jardiance Empagliflozin Brand 70 $66,101
Tresiba Flextouch U-200 Insulin Degludec Brand 47 $39,233
Januvia Sitagliptin Phosphate Brand 44 $35,630
Xarelto Rivaroxaban Brand 32 $25,926
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 37 $22,989
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 24 $18,819

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$37,085

Of which drugs: $6,262

Medicare patients

167

Average age 73

Services billed

806

80 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 31%
Chronic kidney disease 30%
Depression 22%
Ischemic heart disease 19%
COPD 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 53 53 $4,173
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 186 $105

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $185
$185 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $102
$102 37 —
VRAYLAR
  • AbbVie, Inc. $79
$79 — —
NURTEC ODT
  • PFIZER INC. $77
$77 — —
ZAVZPRET
  • PFIZER INC. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record